The ATXN1L Knockout HeLa Polyclonal Cells comprise a heterogeneous population of HeLa cells subjected to CRISPR/Cas9-mediated disruption of the ATXN1L gene, generating a loss-of-function model to investigate the roles of ATXN1L in transcriptional regulation and signaling. This polyclonal knockout pool preserves genetic diversity while uniformly targeting the locus, enabling robust functional studies without clonal isolation artifacts.
The parental HeLa cell line, derived from human cervical carcinoma, is HPV18-positive and characterized by E6-mediated p53 degradation and E7-mediated Rb inactivation, leading to aberrant cell cycle progression and sustained proliferation. These cells exhibit an adherent epithelial morphology and are widely utilized in cancer biology for studying oncogenic signaling, transcriptional dysregulation, and drug responses.
ATXN1L functions as an RNA-binding transcription co-regulator that forms a repressor complex with CIC, directly suppressing expression of ETV1, ETV4, and ETV5 transcription factors. Upon activation of the MAPK/ERK pathway, ERK1/2 phosphorylates CIC, targeting it for degradation and thereby relieving transcriptional repression of downstream targets including CCND1, MYC, and SPRY4. This cascade links extracellular mitogenic signals to gene expression programs that control proliferation and migration. Additional interacting partners such as ATXN1, ATXN2, RBPMS, and PABPC1 further modulate ATXN1L function, while regulators like Notch signaling and miR-130a-3p fine-tune its activity.
In the HeLa context, loss of ATXN1L abrogates CIC-dependent transcriptional repression, potentially leading to constitutive expression of ETV family oncogenes and aberrant activation of cell cycle and survival pathways. This model is particularly informative for dissecting how ATXN1L-dependent repression counteracts HPV-driven transformation, as well as for exploring synthetic interactions with p53 and Rb deficiency. The polyclonal background mitigates clonal drift, making it suitable for pooled functional screens or pharmacogenomic studies.
Researchers can employ this knockout model in diverse applications including Western blotting and RT-qPCR to confirm target disruption, RNA-seq for transcriptome profiling, ChIP-qPCR to assess CIC complex occupancy, and phospho-ERK analysis to interrogate MAPK pathway status. Functional assays such as wound healing, cell proliferation, and drug sensitivity tests enable dissection of ATXN1L??s role in migration and therapy resistance. This polyclonal knockout pool serves as a versatile tool for studies in cancer signaling, neurodegenerative disease mechanisms, and CIC repressor complex biology. For additional information or custom modifications, please contact Ascent Research.
